Lifeway Foods Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
Consolidated Balance Sheets
March 31, 2025 and December 31, 2024
| March 31, 2025 | December 31, | |
|---|---|---|
| (Unaudited) | 2024 | |
| Current assets | ||
| Cash and cash equivalents | $19,446 | $16,728 |
| Accounts receivable, net of allowance for credit losses and discounts & allowances of $2,030 and $1,590 at March 31, 2025 and December 31, 2024, respectively | 16,684 | 15,424 |
| Inventories, net | 9,241 | 8,678 |
| Prepaid expenses and other current assets | 2,007 | 2,144 |
| Refundable income taxes | – | 631 |
| Total current assets | 47,378 | 43,605 |
| Property, plant and equipment, net | 28,112 | 26,862 |
| Operating lease right-of-use asset | 109 | 118 |
| Goodwill | 11,704 | 11,704 |
| Intangible assets, net | 6,223 | 6,358 |
| Other assets | 141 | 1,900 |
| Total assets | $93,667 | $90,547 |
| Current liabilities | ||
| Accounts payable | $11,635 | $10,401 |
| Accrued expenses | 3,939 | 5,103 |
| Accrued income taxes | 795 | – |
| Total current liabilities | 16,369 | 15,504 |
| Operating lease liabilities | 68 | 70 |
| Deferred income taxes, net | 3,062 | 3,062 |
| Total liabilities | 19,499 | 18,636 |
| Stockholders’ equity | ||
| Preferred stock, no par value; 2,500 shares authorized; none issued | – | – |
| Common stock, no par value; 40,000 shares authorized; 17,274 shares issued; 15,203 and 15,100 outstanding at March 31, 2025 and December 31, 2024, respectively | 6,509 | 6,509 |
| Treasury stock, at cost | (13,383) | (14,052) |
| Paid-in capital | 2,680 | 4,632 |
| Retained earnings | 78,362 | 74,822 |
| Total stockholders’ equity | 74,168 | 71,911 |
| Total liabilities and stockholders’ equity | $93,667 | $90,547 |
Consolidated Statements of Operations
For the three months ended March 31, 2025 and 2024
(In thousands, except per share data)
| 2025 | 2024 | |
|---|---|---|
| Net Sales | $46,091 | $44,634 |
| Cost of goods sold | 34,254 | 32,438 |
| Depreciation expense | 802 | 661 |
| Total cost of goods sold | 35,056 | 33,099 |
| Gross profit | 11,035 | 11,535 |
| Selling expense | 4,698 | 3,700 |
| General and administrative expense | 4,628 | 4,136 |
| Amortization expense | 135 | 135 |
| Total operating expenses | 9,461 | 7,971 |
| Income from operations | 1,574 | 3,564 |
| Other income (expense): | ||
| Interest expense | (14) | (51) |
| Gain on sales of investments | 3,352 | – |
| Other income (expense), net | 54 | (5) |
| Total other income (expense) | 3,392 | (56) |
| Income before provision for income taxes | 4,966 | 3,508 |
| Provision for income taxes | 1,426 | 1,082 |
| Net income | $3,540 | $2,426 |
| Net earnings per common share: | ||
| Basic | $0.23 | $0.17 |
| Diluted | $0.23 | $0.16 |
| Weighted average common shares outstanding: | ||
| Basic | 15,134 | 14,691 |
| Diluted | 15,333 | 15,222 |
Consolidated Statements of Stockholders’ Equity
| Common Stock | |||||||
|---|---|---|---|---|---|---|---|
| Issued · In treasury · Paid-In · Retained · Total | |||||||
| Shares | $ | Shares | $ | Capital | Earnings | Equity | |
| Balance, January 1, 2024 | 17,274 | $6,509 | (2,583) | $(16,695) | $4,825 | $65,797 | $60,436 |
| Stock-based compensation | – | – | – | – | 673 | – | 673 |
| Net income | – | – | – | – | – | 2,426 | 2,426 |
| Balance, March 31, 2024 | 17,274 | $6,509 | (2,583) | $(16,695) | $5,498 | $68,223 | $63,535 |
Consolidated Statements of Stockholders’ Equity
| Common Stock | |||||||
|---|---|---|---|---|---|---|---|
| Issued · In treasury · Paid-In · Retained · Total | |||||||
| Shares | $ | Shares | $ | Capital | Earnings | Equity | |
| Balance, January 1, 2025 | 17,274 | $6,509 | (2,174) | $(14,052) | $4,632 | $74,822 | $71,911 |
| Issuance of Common Stock | – | – | 103 | 669 | (2,278) | – | (1,609) |
| Stock-based compensation | – | – | – | – | 326 | – | 326 |
| Net income | – | – | – | – | – | 3,540 | 3,540 |
| Balance, March 31, 2025 | 17,274 | $6,509 | (2,071) | $(13,383) | $2,680 | $78,362 | $74,168 |
Consolidated Statements of Cash Flows
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income | $3,540 | $2,426 |
| Adjustments to reconcile net income to operating cash flow: | ||
| Depreciation and amortization | 937 | 796 |
| Stock-based compensation | 326 | 673 |
| Non-cash interest expense | 3 | 2 |
| Gain on sale of investments | (3,352) | – |
| Fair value loss on investment | 20 | – |
| (Increase) decrease in operating assets: | ||
| Accounts receivable | (1,259) | (1,189) |
| Inventories | (563) | 974 |
| Prepaid expenses and other current assets | 136 | 31 |
| Refundable income taxes | 631 | (378) |
| Increase (decrease) in operating liabilities: | ||
| Accounts payable | 1,401 | (6) |
| Accrued expenses | (2,765) | (1,309) |
| Accrued income taxes | 795 | (474) |
| Net cash (used in) provided by operating activities | (150) | 1,546 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,219) | (2,469) |
| Proceeds from sale of investments | 5,152 | – |
| Net cash provided by (used in) investing activities | 2,933 | (2,469) |
| Cash flows from financing activities: | ||
| Repayment of note payable | – | (250) |
| Payment of deferred financing costs | (65) | – |
| Net cash used in financing activities | (65) | (250) |
| Net increase (decrease) in cash and cash equivalents | 2,718 | (1,173) |
| Cash and cash equivalents at the beginning of the period | 16,728 | 13,198 |
| Cash and cash equivalents at the end of the period | $19,446 | $12,025 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes, net of (refunds) | $– | $1,934 |
| Cash paid for interest | $11 | $50 |
| Non-cash investing activities | ||
| Accrued purchase of property and equipment | $239 | $192 |
| Right-of-use assets obtained in exchange for lease obligations | $8 | $– |
Notes to Consolidated Financial Statements
(In thousands, except per share data)
Note 1 –Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information, and do not include certain information and footnote disclosures required for complete, audited financial statements. In the opinion of management, these statements include all adjustments necessary for a fair presentation of the results of all interim periods reported herein. The consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Results of operations for any interim period are not necessarily indicative of future or annual results.
Principles of consolidation
The consolidated financial statements include the accounts of Lifeway Foods, Inc. and all its wholly owned subsidiaries (collectively “Lifeway” or the “Company”). All significant intercompany accounts and transactions have been eliminated.
**Note 2 –Summary of Significant Accounting Policies **
Our significant accounting policies, which are summarized in detail in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, have not materially changed. The following is a description of certain of our significant accounting policies.
Use of estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in preparing the consolidated financial statements include the reserve for promotional allowances, the valuation of goodwill and intangible assets, stock-based and incentive compensation, and deferred income taxes.
Cash and cash equivalents
Lifeway considers cash and all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates or equals fair value due to their short-term nature.
Lifeway from time to time may have bank deposits in excess of insurance limits of the Federal Deposit Insurance Corporation. The Company places its cash and cash equivalents with high credit quality financial institutions. Lifeway has not experienced any losses in such accounts and believes the financial risks associated with these financial instruments are minimal.
Advertising and promotional costs
Advertising costs are expensed as incurred and reported in Selling expense in the Company’s consolidated statement of operations. Total advertising expense was $2,136 and $1,372 for the three months ended March 31, 2025 and 2024, respectively.
Fair value measurements
In February 2025, the Company’s $1,800 equity investment in Simple Mills was liquidated as a result of the sale of Simple Mills. The Company received cash proceeds of $5,152 and recognized a gain on the sale of investment of $3,352 during the three months ended March 31, 2025.
Segments
The Company is managed as a single reportable segment. The Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), reviews financial information on an aggregate basis for purposes of allocating resources and assessing financial performance, as well as for making strategic operational decisions and managing the organization. Substantially all of Lifeway’s consolidated revenues relate to the sale of cultured dairy products that it produces using the same processes and materials and are sold to consumers through a common network of distributors and retailers in the United States.
Recent accounting pronouncements
Issued but not yet effective
In November 2024, the Financial Accounting Standards Board (“FASB”) issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Topic 220-40): Disaggregation of Income Statement Expenses. The new standard requires additional disclosure of certain amounts included in the expense captions presented on the Statement of Operations as well as disclosures about selling expenses. The new standard is effective on a prospective basis, with the option for retrospective application, for our annual period ending December 31, 2027, and our interim periods during the fiscal year ending December 31, 2028. The new standard does not affect recognition or measurement in the Company’s consolidated financial statements. Upon adoption, the impact of ASU 2024-03 will be limited to certain notes to the Consolidated Financial Statements.
In December 2023, the FASB issued ASU No. 2023-09: Income Taxes (Topic 740): Improvements to Income Tax Disclosures that requires entities to disclose additional information about federal, state, and foreign income taxes primarily related to the income tax rate reconciliation and income taxes paid. The new standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The new standard is effective for our fiscal year ending December 31, 2025, and our interim periods during the fiscal year ending December 31, 2026. The guidance does not affect recognition or measurement in the Company’s consolidated financial statements. Upon adoption, the impact of ASU 2023-09 will be limited to certain notes to the Consolidated Financial Statements.
Note 3 –Inventories, net
| Schedule of inventories | ||
|---|---|---|
| March 31, 2025 | December 31, 2024 | |
| Ingredients | $2,673 | $2,519 |
| Packaging | 2,836 | 2,855 |
| Finished goods | 3,732 | 3,304 |
| Total inventories, net | $9,241 | $8,678 |
Note 4 –Property, Plant and Equipment, net
| Schedule of property, plant and equipment | ||
|---|---|---|
| March 31, 2025 | December 31, 2024 | |
| Land | $1,565 | $1,565 |
| Buildings and improvements | 23,738 | 23,520 |
| Machinery and equipment | 38,002 | 38,181 |
| Vehicles | 477 | 477 |
| Office equipment | 758 | 758 |
| Construction in process | 3,927 | 2,163 |
| 68,467 | 66,664 | |
| Less accumulated depreciation | (40,355) | (39,802) |
| Total property, plant and equipment, net | $28,112 | $26,862 |
**Note 5 –Goodwill and Intangible Assets **
Goodwill
Goodwill consisted of the following:
| Schedule of goodwill | |
|---|---|
| Total | |
| Goodwill | $12,948 |
| Accumulated impairment losses | (1,244) |
| $11,704 | |
| Goodwill | $12,948 |
|---|---|
| Accumulated impairment losses | (1,244) |
| $11,704 |
Intangible Assets
Other intangible assets, net consisted of the following:
| Schedule of other intangible assets | ||||||
|---|---|---|---|---|---|---|
| March 31, 2025 · December 31, 2024 | ||||||
| Gross · Net · Gross · Net | ||||||
| Carrying | Accumulated | Carrying | Carrying | Accumulated | Carrying | |
| Amount | Amortization | Amount | Amount | Amortization | Amount | |
| Recipes | $44 | $(44) | $– | $44 | $(44) | $– |
| Customer lists and other customer related intangibles | 4,529 | (4,529) | – | 4,529 | (4,529) | – |
| Customer relationships | 3,385 | (1,572) | 1,813 | 3,385 | (1,532) | 1,853 |
| Brand names | 7,948 | (3,538) | 4,410 | 7,948 | (3,443) | 4,505 |
| Formula | 438 | (438) | – | 438 | (438) | – |
| Total intangible assets, net | $16,344 | $(10,121) | $6,223 | $16,344 | $(9,986) | $6,358 |
Estimated amortization expense on intangible assets for the next five years is as follows:
| Schedule of future amortization expense on intangible assets | |
|---|---|
| Year | Amortization |
| Nine months ended December 31, 2025 | $405 |
| 2026 | $540 |
| 2027 | $540 |
| 2028 | $540 |
| 2029 | $540 |
The weighted-average remaining amortization expense period for the customer relationship and brand name intangible assets is 11.3 and 11.6 years, respectively, as of March 31, 2025. The weighted-average remaining amortization expense period for total intangible assets is 11.5 years as of March 31, 2025.
**Note 6 –Accrued Expenses **
Accrued expenses consisted of the following:
| Schedule of accrued expenses | ||
|---|---|---|
| March 31, 2025 | December 31, 2024 | |
| Payroll and incentive compensation | $2,902 | $4,188 |
| Real estate taxes | 364 | 468 |
| Utilities | 284 | 193 |
| Current portion of operating lease liabilities | 41 | 47 |
| Other | 348 | 207 |
| Total accrued expenses | $3,939 | $5,103 |
Note 7 –Debt
Revolving Credit Facility
On February 5, 2025, the Company entered into the Fifth Modification to the Amended and Restated Loan and Security Agreement (the “Fifth Modification”) with its current lender. The Fifth Modification, among other things, (i) increased the commitment for revolving loans under the Credit Agreement from $5,000 to $25,000, with interest payable at either the lender Base Rate (the Prime Rate minus 1.00%) or the SOFR plus 1.75%, (ii) extended the termination date of the Credit Agreement to February 5, 2028, (iii) replaced the quarterly minimum working capital financial covenant with a financial covenant to maintain a maximum cash flow leverage ratio of no greater than 2.00 to 1.00 for each fiscal quarter commencing with the fiscal quarter ending March 31, 2025, (iv) increased the quarterly unused revolving line of credit fee to 0.25%, and (v) increased the letter of credit fee to 1.00%. The remaining material terms and conditions of the Credit Agreement remain substantially unchanged. The Company had no outstanding borrowings at the time of entry into the Fifth Modification.
As of March 31, 2025, the Company had $0 outstanding under the Revolving Credit Facility. The Company had $25,000 available for future borrowings under the Revolving Credit Facility as of March 31, 2025.
Lifeway was in compliance with the fixed charge coverage ratio and maximum cash flow leverage ratio covenants at March 31, 2025.
Note 8 –Leases
The Company leases certain machinery and equipment with fixed base rent payments and variable costs based on usage. Remaining lease terms for these leases range from less than one year to six years. The Company includes lease extension options, if applicable and reasonably certain to be exercised, in the calculation of the right-of-use asset and lease liabilities. Lifeway includes only fixed payments for lease components in the measurement of the right-of-use asset and lease liability. Variable lease payments are those that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. There are no residual value guarantees. Lifeway does not currently have leases which meet the finance lease classification as defined under ASC 842.
Lifeway treats contracts as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, it directs the use of the asset and obtains substantially all the economic benefits of the asset.
Right-of-use assets and lease liabilities are measured and recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Lifeway has elected the practical expedient to combine lease and non-lease components into a single component for all of its leases. When the Company is unable to determine an implicit interest rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments for those leases. Lifeway includes options to extend or terminate the lease in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise such options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
The Company does not record leases with an initial term of 12 months or less on the balance sheet. Expense for these short-term leases is recorded on a straight-line basis over the lease term. Total lease expense was $37 and $35 (including short term leases) for the three months ended March 31, 2025 and 2024, respectively.
Future maturities of lease liabilities were as follows:
| Schedule of future maturities of lease liabilities | |
|---|---|
| Year | Operating Leases |
| Nine months ended December 31, 2025 | $38 |
| 2026 | 35 |
| 2027 | 25 |
| 2028 | 17 |
| 2029 | 10 |
| Thereafter | - |
| Total lease payments | 125 |
| Less: Interest | (16) |
| Present value of lease liabilities | $109 |
The weighted-average remaining lease term for its operating leases was 3.3 years as of March 31, 2025. The weighted average discount rate of its operating leases was 8.79% as of March 31, 2025. Cash paid for amounts included in the measurement of lease liabilities was $19 and $24 for the three months ended March 31, 2025 and 2024, respectively.
**Note 9 –Commitments and contingencies **
Litigation
Lifeway from time to time, may be involved in various legal proceedings, claims, disputes, regulatory matters, audits, and proceedings arising in the ordinary course of, or incidental, to the Company’s business, including commercial disputes, product liabilities, intellectual property matters and employment-related matters.
Lifeway records provisions in the consolidated financial statements for pending legal matters when it believes it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company evaluates, on a periodic basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, it does not establish an accrued liability. Currently, none of its accruals for outstanding legal matters are material individually or in the aggregate to its financial position and it is management’s opinion that the ultimate resolution of these outstanding legal matters will not have a material adverse effect on its business, financial condition, results of operations, or cash flows. However, if the Company is ultimately required to make payments in connection with an adverse outcome, it is possible that such contingency could have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.
Note 10 –Income taxes
Income taxes were recognized at effective rates of 28.7% and 30.8% for the three months ended March 31, 2025 and 2024, respectively. The change in the Company’s effective tax rate is primarily driven by changes in the amount of non-deductible officer compensation and non-deductible stock-based compensation expense.
The Company calculates the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate for the full year, excluding unusual or infrequently occurring discrete items, and applies that rate to income (loss) before provision for income taxes for the period.
The Company’s effective tax rate may change from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.
Note 11 –Stock-based and Other Compensation
Employee Incentive and Non-Employee Director Plans
The Board of Directors adopted, and the Company’s stockholders approved, the “Lifeway Foods, Inc. 2022 Omnibus Incentive Plan” (the “Plan”). Under the Plan, the Compensation Committee may grant awards of various types of compensation, including nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, cash-based awards and other stock-based awards to qualifying employees. The maximum number of shares authorized to be awarded under the Plan is 3.25 million. As of March 31, 2025,2.62 million shares remain available to award under the Plan.
Lifeway stockholders approved the 2022 Non-Employee Director Equity and Deferred Compensation Plan (the “2022 Director Plan”), which authorizes the grant of restricted stock units. The maximum aggregate number of shares that may be issued under the 2022 Director Plan is 500 thousand. As of March 31, 2025,392 thousand shares remain available to award under the 2022 Director Plan.
Total compensation expense related to stock-based payments and the related income tax benefit recognized in net income are as follows:
| Schedule of compensation expense related to stock-based payments | ||
|---|---|---|
| Three Months Ended | ||
| March 31, | ||
| 2025 | 2024 | |
| (In Thousands) | ||
| Compensation expense related to stock-based payments | $326 | $673 |
| Related income tax benefit | 91 | 65 |
Stock Options
The following table summarizes stock option activity during the three months ended March 31, 2025:
| Schedule of stock option activity | ||||
|---|---|---|---|---|
| Options | Weighted average exercise price | Weighted average remaining contractual life | Aggregate intrinsic value | |
| (In thousands) | ||||
| Outstanding at December 31, 2024 | 30 | $10.42 | 1.21 | $426 |
| Granted | – | – | – | – |
| Exercised | – | – | – | – |
| Forfeited | – | – | – | – |
| Outstanding at March 31, 2025 | 30 | $10.42 | 0.96 | $416 |
| Exercisable at March 31, 2025 | 30 | $10.42 | 0.96 | $416 |
Restricted Stock Units
Restricted stock unit awards generally vest based on the passage of time in approximately three equal installments on each of the first three anniversaries of the grant date. Certain non-employee directors have elected to defer receipt of their awards until their departure from the Board of Directors.
The following table summarizes restricted stock unit activity during the three months ended March 31, 2025.
| Schedule of RSU activity | ||
|---|---|---|
| Restricted Stock Units | Weighted Average Grant Date Fair Value | |
| (In thousands) | ||
| Outstanding at December 31, 2024 | 190 | $8.77 |
| Granted | 18 | 24.53 |
| Shares issued upon vesting | (11) | 13.73 |
| Forfeited | (8) | 8.47 |
| Outstanding at March 31, 2025 | 189 | $10.00 |
| Vested and deferred at March 31, 2025 | 73 | $7.88 |
Unrecognized compensation expense related to nonvested restricted stock units was $887 as of March 31, 2025 and will be recognized over a weighted average period of 1.3 years. The grant date fair value of the awards is equal to the Company’s closing price on the grant date.
Performance Units
Performance unit awards are granted to certain members of management. These awards include both service and performance conditions.
For performance unit awards granted in fiscal years 2023 through 2025, performance goals are established upfront and are measured over a cumulative three-year measurement period. The performance goals are 1) 3-year cumulative net revenue, and 2) 3-year cumulative adjusted EBITDA. The target number of performance unit awards are weighted 50% on net revenue and 50% on adjusted EBITDA. Participants may earn more or less than the target number of units, and are bound by minimum and maximum thresholds of net revenue and adjusted EBITDA. The PSU awards will be earned and will vest, if at all, after the end of the three-year measurement period. These awards will be converted to stock upon vesting.
The following table summarizes performance unit activity during the three months ended March 31, 2025.
| Schedule of performance units | ||
|---|---|---|
| Performance Units | Weighted Average Grant Date Fair Value | |
| (In thousands) | ||
| Nonvested at December 31, 2024 | 306 | $8.08 |
| Granted (1) | 91 | 13.45 |
| Shares issued upon vesting | (168) | 6.25 |
| Forfeited | (30) | 8.01 |
| Nonvested at March 31, 2025 | 199 | $12.10 |
| (1) | Includes 55 thousand additional shares granted in connection with the vesting of the 2022 award in 2025 due to above-target performance in accordance with the terms of the award. |
Unrecognized compensation expense related to nonvested performance units is estimated to be approximately $2,076 as of March 31, 2025 and are expected to be recognized over a weighted average period of 1.4 years. The grant date fair value of the awards is equal to the Company’s closing price on the grant date.
Retirement Benefits
Lifeway has a defined contribution plan which is available to substantially all full-time employees. Under the terms of the plan, the Company matches employee contributions under a prescribed formula. For the three months ended March 31, 2025 and 2024, total contribution expense recognized in the consolidated statements of operations was $261 and $193, respectively.
Note 12 -Earnings Per Share
The following table summarizes the effects of the share-based compensation awards on the weighted average number of shares outstanding used in calculating diluted earnings per share:
| Schedule of weighted average number of shares outstanding | ||
|---|---|---|
| Three Months Ended | ||
| March 31, | ||
| 2025 | 2024 | |
| (In Thousands) | ||
| Weighted average common shares outstanding | 15,134 | 14,691 |
| Assumed exercise/vesting of equity awards | 199 | 531 |
| Weighted average diluted common shares outstanding | 15,333 | 15,222 |
Note 13 –Disaggregation of Revenue and Significant Customers
The Company has one reportable segment, which manufactures and distributes cultured dairy products. Our products are produced using the same processes and materials and are sold to consumers through a common network of distributors and retailers. The Company derives revenue primarily in North America and manages the business activities on a consolidated basis. The business activities include selling cultured dairy products across various channels including retail-direct, distributor, and direct store delivery in a refrigerated format. We operate our business with a centralized financial systems infrastructure, and we share centralized resources for procurement and general and administrative activities. The accounting policies of the segment are the same as those described in the Summary of Significant Accounting Policies for the Company. Refer to Note 1 for additional information.
The Chief Executive Officer (“CEO”) has been identified as our Chief Operating Decision Maker (“CODM”). The Company manages operations on a company-wide basis, thereby making determinations as to the allocation of resources as one segment. The CODM uses consolidated single-segment financial information to assess performance for the segment and decides how to allocate resources based on the Company’s consolidated net income (loss), which is reported on the Consolidated Statement of Operations. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets.
Products from which the reportable segment derives its revenue
Lifeway’s primary product is drinkable kefir. The Company manufactures (directly or through a co-manufacturer) and markets products under the Lifeway, Fresh Made, and GlenOaks Farms brand names, as well as under private labels on behalf of certain customers.
The Company’s product categories are:
| · | Drinkable kefir, a cultured dairy product sold in a variety of organic and non-organic sizes, flavors, and types. |
| · | European-style soft cheeses, including farmer cheese, white cheese, and Sweet Kiss. |
| · | Cream and other, which primarily consists of cream, a byproduct of raw milk processing. |
| · | Drinkable yogurt, sold in a variety of sizes and flavors. |
| · | ProBugs, a line of kefir products designed for children. |
| · | Other dairy, which primarily consists of Fresh Made butter and sour cream. |
Net sales of products by category were as follows for the three months ended March 31:
| Schedule of segment products by category | ||||
|---|---|---|---|---|
| 2025 | 2024 | |||
| In thousands | $ | % | $ | % |
| Drinkable Kefir other than ProBugs | 38,050 | 83% | 36,533 | 82% |
| Cheese | 3,812 | 8% | 3,515 | 8% |
| Cream and other | 2,459 | 5% | 1,816 | 4% |
| Drinkable Yogurt | 634 | 1% | 1,536 | 3% |
| ProBugs Kefir | 746 | 2% | 866 | 2% |
| Other dairy | 390 | 1% | 368 | 1% |
| Net Sales | 46,091 | 100% | 44,634 | 100% |
Significant Customers
Sales are predominately to companies in the retail food industry located within the United States. Two major customers accounted for a total of 24% and 25% of net sales for the three months ended March 31, 2025 and 2024, respectively.
Geographic Information
Net sales outside the of the United States represented less than 1% of total consolidated net sales for the three months ended March 31, 2025 and 2024. Net sales are determined based on the destination where the products are shipped by Lifeway.
All the Company’s long-lived assets are in the United States.
Note 14 –Shareholder Rights Plan
On November 4, 2024, the Company adopted a Shareholder Rights Agreement (the “Rights Agreement”) and designated 40 shares of preferred stock as Series A Junior Participating Preferred Stock, none of which are issued or outstanding as of December 31, 2024. Pursuant to the Rights Agreement, the Company’s board of directors declared a dividend of one preferred share purchase right (each a “Right”) for each outstanding share of Company common stock to stockholders of record as of the close of business on November 18, 2024. Each Right entitles its holder, subject to the terms of the Rights Agreement, to purchase from the Company one one-thousandth of one share of Series A Junior Participating Preferred Stock, no par value, of the Company at an exercise price of $130.00 per Right, subject to adjustment. Rights will attach to any shares of Company common stock that become outstanding after November 18, 2024 and prior to the earlier of the Distribution Time (as defined in the Rights Agreement) and the redemption or expiration of the Rights, and in certain other circumstances described in the Rights Agreement. The Right expires at the end of November 4, 2025, or earlier if exercised.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.